Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$209.83
-0.4%		$203.76
$131.52
▼
$219.72
$31.12B0.171.01 million shs554,425 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$51.24
+1.2%		$54.19
$33.76
▼
$57.57
$12.70B0.442.73 million shs2.34 million shs
Natera, Inc. stock logo
NTRA
Natera
$309.93
-0.3%		$263.76
$156.71
▼
$326.03
$44.80B1.511.29 million shs1.27 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$203.71
+0.8%		$181.62
$35.42
▼
$208.76
$43.30B1.391.77 million shs784,220 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-0.39%+0.91%+6.38%+8.75%+55.19%
Exelixis, Inc. stock logo
EXEL
Exelixis
+1.24%-5.23%-7.76%+2.21%+33.13%
Natera, Inc. stock logo
NTRA
Natera
-0.27%-3.78%+11.74%+66.31%+96.53%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+0.85%-0.70%+10.45%+39.85%+465.17%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$209.83
-0.4%		$203.76
$131.52
▼
$219.72
$31.12B0.171.01 million shs554,425 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$51.24
+1.2%		$54.19
$33.76
▼
$57.57
$12.70B0.442.73 million shs2.34 million shs
Natera, Inc. stock logo
NTRA
Natera
$309.93
-0.3%		$263.76
$156.71
▼
$326.03
$44.80B1.511.29 million shs1.27 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$203.71
+0.8%		$181.62
$35.42
▼
$208.76
$43.30B1.391.77 million shs784,220 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-0.39%+0.91%+6.38%+8.75%+55.19%
Exelixis, Inc. stock logo
EXEL
Exelixis
+1.24%-5.23%-7.76%+2.21%+33.13%
Natera, Inc. stock logo
NTRA
Natera
-0.27%-3.78%+11.74%+66.31%+96.53%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+0.85%-0.70%+10.45%+39.85%+465.17%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.58
Moderate Buy$227.078.22% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.32
Hold$49.79-2.84% Downside
Natera, Inc. stock logo
NTRA
Natera
2.82
Moderate Buy$319.383.05% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.91
Moderate Buy$161.79-20.58% Downside

Current Analyst Ratings Breakdown

Latest EXEL, NTRA, RVMD, and BIIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
Biogen Inc. stock logo
BIIB
Biogen
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$300.00
8/13/2026
Natera, Inc. stock logo
NTRA
Natera
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$315.00 ➝ $365.00
8/12/2026
Biogen Inc. stock logo
BIIB
Biogen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C) ➝ Hold (C-)
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Stephens logo
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$305.00 ➝ $350.00
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$290.00 ➝ $360.00
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$249.00 ➝ $363.50
8/11/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B) ➝ Buy (A-)
8/11/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$210.00 ➝ $231.00
8/10/2026
Natera, Inc. stock logo
NTRA
Natera
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$355.00
8/10/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$220.00
(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.13$22.54 per share9.31$127.56 per share1.64
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.44B5.21$3.06 per share16.72$7.44 per share6.89
Natera, Inc. stock logo
NTRA
Natera
$2.31B19.37N/AN/A$12.64 per share24.52
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/A$12.16 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6537.1412.806.518.32%11.18%6.88%10/29/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1816.1113.771.5135.33%42.17%31.76%11/3/2026 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.36N/A30,993.00N/A-7.11%-11.38%-7.87%N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$8.82N/AN/AN/AN/A-88.20%-57.85%N/A

Latest EXEL, NTRA, RVMD, and BIIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939-$0.47+$0.0239-$0.47$661.24 million$752.75 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
8/5/2026Q2 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.04-$3.06-$1.02-$3.06$1.77 millionN/A
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
Natera, Inc. stock logo
NTRA
Natera
N/A
3.00
2.83
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.40
11.38
11.38

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Natera, Inc. stock logo
NTRA
Natera
99.90%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
Natera, Inc. stock logo
NTRA
Natera
5.05%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140144.14 million136.87 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250214.34 million198.05 millionOptionable

Recent News About These Companies

Revolution Medicines (RVMD) Receives a Buy from Truist Financial
August 12 at 12:18 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3801842/revolution-medicines-rvmd-receives-a-buy-from-truist-financial/
Why Revolution Medicines May Be Big Pharma's Next Takeover Target
August 12 at 8:50 AM  |  247wallst.comhttps://247wallst.com/investing/2026/08/12/why-revolution-medicines-may-be-big-pharmas-next-takeover-target/?utm_source=snapi
Tema ETFs LLC Sells 26,443 Shares of Revolution Medicines, Inc. $RVMD
August 12 at 6:31 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-tema-etfs-llc-sells-26443-shares-of-revolution-medicines-inc-rvmd-2026-08-12/
Handelsbanken Fonder AB Raises Stock Position in Revolution Medicines, Inc. $RVMD
August 12 at 5:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-handelsbanken-fonder-ab-raises-stock-position-in-revolution-medicines-inc-rvmd-2026-08-12/
Revolution Medicines (RVMD) Looks Fairly Valued As BeOne Deal Expands Its Asia Reach
August 12 at 1:31 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-rvmd-looks-fairly-023528304.html
Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month High - Should You Buy?
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/revolution-medicines-nasdaqrvmd-sets-new-12-month-high-should-you-buy-2026-08-11/
Bank of America Corp DE Cuts Holdings in Revolution Medicines, Inc. $RVMD
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-cuts-holdings-in-revolution-medicines-inc-rvmd-2026-08-11/
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
August 10, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260810801799/en/beone-medicines-and-revolution-medicines-announce-clinical-development-and-regional-commercialization-collaboration/
Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)
August 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3745020/analysts-are-bullish-on-these-healthcare-stocks-spyre-therapeutics-syre-revolution-medicines-rvmd/
Assenagon Asset Management S.A. Buys Shares of 200,486 Revolution Medicines, Inc. $RVMD
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-buys-shares-of-200486-revolution-medicines-inc-rvmd-2026-08-09/
Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $240.00
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30949765
Sei Investments Co. Cuts Holdings in Revolution Medicines, Inc. $RVMD
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-sei-investments-co-cuts-holdings-in-revolution-medicines-inc-rvmd-2026-08-08/
'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of blockbuster pancreatic cancer drug
August 7, 2026  |  bizjournals.comhttps://www.bizjournals.com/sanfrancisco/news/2026/08/07/pancreatic-cancer-daraxonrasib-revolution-rvmd.html
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)
August 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/URGN/pressreleases/3717834/analysts-have-conflicting-sentiments-on-these-healthcare-companies-revolution-medicines-rvmd-royalty-pharma-rprx-and-urogen-pharma-urgn/
High Risk, High Reward: Inside The Revolution Medicines Bull Case
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932810-high-risk-high-reward-inside-the-revolution-medicines-bull-case
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970347/rvmd-posts-wider-than-anticipated-loss-in-q2-lifts-26-expense-view?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2970347
Needham & Company LLC Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $240.00
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/needham-company-llc-raises-revolution-medicines-nasdaqrvmd-price-target-to-24000-2026-08-06/
Quantinno Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantinno-capital-management-lp-boosts-stake-in-revolution-medicines-inc-rvmd-2026-08-06/
Revolution Medicines Q2 Earnings Call Highlights
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/revolution-medicines-q2-earnings-call-highlights-2026-08-05/
Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/revolution-medicines-nasdaqrvmd-announces-earnings-results-2026-08-05/
Revolution Medicines Q2 Net Loss Widens
August 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-q2-net-loss-212551304.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A Patriot missile launcher and soldier on an airbase tarmac as an F-35 fighter jet flies overhead at sunset.
RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
By Dan Schmidt | July 26, 2026
Rocket Lab Electron rocket lifts off from coastal pad, plume and smoke rising beside Rocket Lab logo.
Rocket Lab Has Corrected Nearly 50%—Is It Still Too Expensive?
By Ryan Hasson | July 23, 2026
Palantir-branded sphere glows in a server room with AI graphics, underscoring the company’s enterprise AI capabilities.
Palantir's Wild Ride: Inside the Stock Wall Street Can't Agree On
By Chris Markoch | July 17, 2026
SpaceX logo above a rocket on a launch pad at twilight, with a water tower in the background.
Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
By Jeffrey Neal Johnson | August 1, 2026
Illuminated IREN logo stands amid rows of data center buildings and electrical infrastructure at sunset in a desert setting.
IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story
By Jeffrey Neal Johnson | July 21, 2026
Biogen stock logo

Biogen NASDAQ:BIIB

$209.83 -0.82 (-0.39%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$209.81 -0.02 (-0.01%)
As of 08/14/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$51.24 +0.63 (+1.24%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$51.26 +0.02 (+0.03%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Natera stock logo

Natera NASDAQ:NTRA

$309.93 -0.85 (-0.27%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$308.80 -1.13 (-0.36%)
As of 08/14/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$203.71 +1.71 (+0.85%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$203.42 -0.29 (-0.14%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas